World Pharma Industry Value Report 2017 - From R&D Investment to Externalization

Dublin, Nov. 09, 2017 -- The "From R&D Investment to Externalization: Where is the Pharma Industry Maximizing Value?" report has been added to Research and Markets' offering.

Pharmaceutical companies are attempting to maximize value from all angles, including internal investment in R&D and externalization via deal-making. The growth in these two models has had an impact on both revenue derived from internally developed products, as well as externalized drugs.

Key Topics Covered:

1 EXECUTIVE SUMMARY

2 OVERALL TRENDS

3 R&D INVESTMENT TRENDS

• Overall R&D Investment trends
• Peer set R&D investment trends
• R&D productivity
• Bibliography

4 BIG PHARMA LICENSING TRENDS

• Alliance volume and value
• In-licensing and out-licensing
• Phase trends
• Therapy area trends
• Bibliography

5 REVENUE EXTERNALIZATION TRENDS

• Higher volume of unpartnered drugs, but partnered candidates are growing faster
• Externalized revenue growth due to M&A, co-developed drugs, and acquired products
• Peer set externalized revenue trends
• Higher average per-drug revenue expected for externalized products
• Bibliography

6 APPENDIX

• Scope
• Methodology
  

For more information about this report visit https://www.researchandmarkets.com/research/f39gpt/from_randd

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Pharmaceuticals